Autologous Peripheral Stem-Cell Transplantation. Health Technology AssessmentNumber 5

摘要

Autologous peripheral stem-cell transplantation (APSCT) has been extensivelyapplied to support cancer patients who have undergone high-dose chemotherapy (HDCT) and suffer from the effects of otherwise prolonged or irreversible myelosuppression. The APSCT process involves harvesting of autologous progenitor cells from a pateient's circulating blood (via leukapheresis), cryopreservation of the cells, and subsequent intravenous infusion for bone marrow hematopoietic reconstruction (HR). Although pluripotent stem cells, capable of multilinage differentiation, cannot be distinguished by morphologic criteria, they can be characterized as being CD34+cells capable of indefinite self-renewal in situ and long-term self-renewal in cell cultures. Bone marrow and peripheral blood are common sources of autologous progenitor cells. Current techniques to identify and seperate CD34+cells for use in APSCT have resulted in fewer tumor cells being infused than if unseperated peripheral stem cells (PSC) were transplanted, with